Curtiland Deville, Jr., M.D., is the clinical director of radiation oncology and the co-director of the Prostate Cancer Multidisciplinary Clinic at Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, the future site of proton therapy for Johns Hopkins Medicine. Dr. Deville is also an associate professor in the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University School of Medicine, as well as the Department of Oncology. He is board certified in radiation oncology by the American Board of Radiology.
Dr. Deville has an expertise in genitourinary malignancies, including prostate cancer, and soft tissue sarcomas. He also already has an expertise in proton therapy, having treated several hundreds of patients at the University of Pennsylvania, the sixth academic center opened in the country.
Dr. Deville earned his medical degree from Brown University and completed a Doris Duke clinical research fellowship at the Yale Cancer Center. He completed his transitional year internship in internal medicine at Harbor Hospital Center and a residency in radiation oncology at the Hospital of the University of Pennsylvania, where he joined the junior faculty as an assistant professor and served as clinical chief of the genitourinary and sarcoma services in the Department of Radiation Oncology. Dr. Deville currently serves as an adjunct assistant professor in the Department of Radiation Oncology at the University of Pennsylvania.
Dr. Deville has been part of the Who's Who in Medicine and Healthcare list for several years, and was named a University of Pennsylvania Health System Health Care Hero for several years. He was also named one of America's Top Oncologists by Consumers' Research Council of America.
Dr. Deville is the current chair of the American Society of Radiation Oncology's Committee on Health Equity, Diversity and Inclusion. He is also a member of the American Society of Clinical Oncology and its Health Disparities Committee; and the American College of Radiology and its Commission for Women and General Diversity; as well as the National Medical Association and the Connective Tissue Oncology Society.
Dr. Deville's research interests involve enhancing the therapeutic ratio of cancer treatment using proton and photon therapy by improving tumor targeting and reducing normal tissue toxicity. He analyzes toxicity rates with modern radiation techniques for prostate cancer and has evaluated the implementation of image-guided radiation techniques, such as radiofrequency-guide tracking, cone beam CT, an endorectal-filled water balloon, and proton therapy for novel indications and issues in prostate cancer such as pencil beam scanning, robustness evaluation, and post-prostatectomy and pelvic nodal irradiation. Dr. Deville is a senior editor for Advances in Radiation Oncology, as well as a reviewer for several journals that focus on radiation oncology.
Dr. Deville also has a research and educational interest in physician workforce diversity in radiation oncology and training specialties that are disproportionately underrepresented with respect to race, ethnicity and gender. He has published research, lectured, and designed programming and discussions on this topic.